Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COZAAR vs ANEXSIA 5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Losartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. It also reduces proteinuria and slows progression of renal disease by decreasing intraglomerular pressure.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Hypertension,Nephropathy in patients with type 2 diabetes and hypertension,Hypertension with left ventricular hypertrophy (to reduce risk of stroke)
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Plasma half-life of losartan: approximately 2 hours; active metabolite E-3174: 6–9 hours. Clinical context: once-daily dosing due to prolonged receptor blockade by metabolite
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Losartan is extensively metabolized in the liver via CYP2C9 and CYP3A4 to its active metabolite, E-3174, which is more potent than the parent drug. E-3174 is further metabolized to inactive metabolites. Both losartan and E-3174 are excreted in urine and feces.
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Renal (35% as unchanged drug and 18% as active metabolite), biliary/fecal (approximately 60% of radiolabeled dose recovered in feces)
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
≥99% (primarily albumin); losartan ≥98.7%, active metabolite ≥99.8%
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
Losartan: 34 L (0.47 L/kg for 70 kg adult); active metabolite: 12 L. Indicates limited extravascular distribution
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Oral: about 33% (losartan); active metabolite bioavailability not directly reported but formed via first-pass metabolism
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, initial dose is 25 mg orally once daily.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
For Child-Pugh Class A or B: initial dose is 25 mg orally once daily; no data for Class C.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
For children ≥6 years: initial dose 0.7 mg/kg (up to 50 mg) orally once daily; maximum 1.4 mg/kg (up to 100 mg) once daily.
Not recommended for children under 18 years due to risk of respiratory depression.
Consider lower initial dose of 25 mg orally once daily due to potential for volume depletion or decreased renal function.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
None
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Fetal toxicity (discontinue when pregnancy is detected); hypotension in volume-depleted patients; renal impairment (monitor serum creatinine and potassium); hyperkalemia; angioedema; dual blockade of renin-angiotensin system (increased risk of hypotension, hyperkalemia, renal dysfunction); hepatotoxicity; monitor for azotemia in renovascular hypertension.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Hypersensitivity to losartan or any component; pregnancy (especially second and third trimesters); concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (e GFR <60 m L/min/1.73m²); history of angioedema related to previous ARB therapy.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
No significant food interactions. However, avoid high-potassium foods (such as bananas, oranges, leafy greens, tomatoes, and avocados) in large amounts if taken with potassium supplements or if renal function is impaired. Limit salt intake as advised for hypertension management. Grapefruit juice does not interact significantly with losartan.
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
Contraindicated in pregnancy. First trimester: Associated with congenital malformations, including renal dysplasia and oligohydramnios. Second and third trimesters: Fetal toxicity (oligohydramnios, pulmonary hypoplasia, skull ossification defects, neonatal anuria, hypotension, and death).
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Not recommended. No data on M/P ratio; excreted in rat milk; potential for adverse effects in nursing infant due to renin-angiotensin system blockade.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Contraindicated; no dose adjustments recommended as use should be avoided; alternative antihypertensives preferred.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Cozaar (losartan) is an angiotensin II receptor blocker (ARB). Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation and periodically thereafter. May cause a reversible rise in serum creatinine, especially in renal artery stenosis. Has a uricosuric effect, modestly lowering uric acid levels. Avoid use in pregnancy (category D). Dose adjustment recommended for hepatic impairment. Can be used as an alternative in patients who develop ACE-inhibitor-induced cough.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Take once daily with or without food; consistency in timing is key.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,May cause dizziness, especially at start; avoid driving until you know how it affects you.,Do not use if pregnant, planning pregnancy, or breastfeeding; discuss contraception with your doctor.,Report symptoms like fainting, rapid heartbeat, or leg swelling to your doctor.,Stay well-hydrated, especially if you experience diarrhea or vomiting, as dehydration can worsen side effects.,Do not stop this medication abruptly; consult your physician before discontinuing.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COZAAR vs ANEXSIA 5/325, answered by our medical review team.
COZAAR is a Angiotensin Receptor Blocker that works by Losartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. It also reduces proteinuria and slows progression of renal disease by decreasing intraglomerular pressure.. ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COZAAR and ANEXSIA 5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COZAAR is: 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.. The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COZAAR and ANEXSIA 5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COZAAR is classified as Category C. Contraindicated in pregnancy. First trimester: Associated with congenital malformations, including renal dysplasia and oligohydramnios. Second and third trimesters: Fetal toxicity . ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.